A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 632 participants.
Also called NCT06235086
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 632 participants
- Registry
-
NCT06235086
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06235086. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-08 (actual); primary completion 2026-02-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- TG103
- Intervention (Drug)
- Dulaglutide
- Lead sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct06235086- Content hash
0b2dda8e9e93350e49fb44343592ff84b169f570a19dcfeb5480b47b24bbe874